# MATISSE (NCT04620200)

> Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab; nivolumab
- Indication: resectable advanced cutaneous squamous cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04620200
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: The Netherlands Cancer Institute
- Conditions: Cutaneous Squamous Cell Carcinoma
- Interventions: Nivolumab; Ipilimumab
- Enrollment: 50
- Primary outcome: Histopathological response rate at standard of care

## Indexed commentary on MATISSE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 10
- X threads: 6
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=matisse-nct04620200

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04620200", "email": "<work email>"}; the inbox owner confirms by the emailed link.